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Abstract 
 
Cancers develop through somatic mutagenesis, however germline genetic variation can 
markedly contribute to tumorigenesis via diverse mechanisms. We discovered and phased 88 
million germline single nucleotide variants, short insertions/deletions, and large structural 
variants in whole genomes from 2,642 cancer patients, and employed this genomic resource to 
study genetic determinants of somatic mutagenesis across 39 cancer types. Our analyses 
implicate damaging germline variants in a variety of cancer predisposition and DNA damage 
response genes with specific somatic mutation patterns. Mutations in the MBD4 DNA 
glycosylase gene showed association with elevated C>T mutagenesis at CpG dinucleotides, a 
ubiquitous mutational process acting across tissues. Analysis of somatic structural variation 
exposed complex rearrangement patterns, involving cycles of templated insertions and 
tandem duplications, in BRCA1-deficient tumours. Genome-wide association analysis 
implicated common genetic variation at the APOBEC3 gene cluster with reduced basal levels 
of somatic mutagenesis attributable to APOBEC cytidine deaminases across cancer types. We 
further inferred over a hundred polymorphic L1/LINE elements with somatic retrotransposition 
activity in cancer. Our study highlights the major impact of rare and common germline variants 
on mutational landscapes in cancer. 
 
Introduction 
  
Tumourigenesis involves somatic mutations arising as a result of exogenous and cell-intrinsic 
factors1,2. Recent efforts to sequence tumour genomes have revealed hundreds of somatically 
mutated genes in cancer3-7. They also uncovered a variety of mutational processes shaping the 
genomic landscapes of cancers8-12. These include G>T transversions attributed to tobacco 
carcinogens13,14, C>T and C>G substitutions attributed to APOBEC cytidine deaminase activity15,16 and 
spontaneous 5-methylcytosine deamination at CpG sites resulting in C>T transitions17. Mutational 
processes mediating genomic structural variants (SVs) are also active in cancer18-23, occasionally 
resulting in massively complex rearrangements (e.g. chromothripsis)22,24-27. 
 
Genetic variants relevant to cancer additionally exist in the germline28,29, and many rare and common 
germline genetic variants have been implicated in cancer susceptibility29,30. Cancer predisposition 
genes frequently partake in fundamental cellular processes including cell cycle regulation and DNA 
repair29, the impairment of which may influence or augment the effects of somatic mutational 
processes18,31. Several studies have implicated rare and common germline cancer susceptibility 
variants in mutational processes18,24,32-34, patterns of selection of somatic variation35,36 and gene 
expression37-40. For example, carriers of pathogenic germline mutations in BRCA1 and BRCA2 
typically exhibit characteristic somatic mutation patterns in breast, ovarian, pancreatic, and prostate 
tumours, and were found to exhibit increased rates of short insertions and deletions (indels), large 
deletions (in breast cancers with BRCA2-deficiency) and tandem duplications (in breast cancers with 
BRCA1-deficiency)18,36,41-44. Germline TP53 mutations have been linked to chromothripsis in 
medulloblastoma24. Furthermore, evidence for germline variation influencing positive selection of 
somatic mutations has been revealed through analyses of single nucleotide polymorphism (SNP) 
arrays and whole exome sequencing (WES) data, exemplified by the identification of a haplotype 
associated with PTEN somatic mutation35,36. These findings emphasize the relevance of studying 
associations between germline and somatic variation, which could be markedly facilitated with the 
availability of unified germline and somatic variant calls in a substantial set of cancer genomes. 
 
Here, we report on the efforts of the Pan-Cancer Analysis of Whole Genomes45 (PCAWG) germline 
variation working group, which constructed standardized whole genome sequencing (WGS)-based 
germline variant callsets in 2,642 cancer patients, to establish a reference resource of heritable 
genetic variants in donors from the International Cancer Genome Consortium (ICGC) and the Cancer 
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Genome Atlas (TCGA). We discovered 88 million germline variants in these donors, including SNVs, 
indels, and SVs. Integrative analyses of these germline variants with somatic SNVs, indels, and SVs 
seen in cancers obtained from these donors led us to uncover novel insights into the relationship of 
germline and somatic variation: We describe >100 active germline LINE/L1 elements mediating 
retrotransposition in cancer; uncover common variation modulating mutagenesis attributed to 
APOBEC3B across tumour types; and identify germline protein-truncating variants (PTV) in a variety 
of genes that associate with patterns of somatic mutation – including germline MBD4 PTV variants, 
which our study implicates in a widespread mutational process.  
 
Results and Discussion 
 
A germline genome variation resource constructed from 2,642 cancer genomes  
We employed several algorithms for germline variant detection in non-cancerous WGS samples from 
2,642 PCAWG donors (Fig. 1A & Methods). The sequencing data, spanning 39 cancer types (Table 
S1) at a mean sequencing coverage of 39-fold, consists of WGS data from ICGC and TCGA studies45, 
which we analysed on high-performance and cloud computing platforms46. Integration of germline 
callsets by variant class yielded a site list with 80.1 million biallelic SNVs (harbouring two allelic states 
in the population), 5.9 million biallelic indels, 1.8 million multi-allelic short (<50bp-sized) variants, as 
well as SVs (defined as variants ≥50bp in size47) including 29,492 biallelic deletions and 23,855 mobile 
element insertions (MEIs) (Table 1). Our germline variant set incorporates genomic regions known to 
be difficult to sequence, including the HLA (human leukocyte antigen) loci that we analysed using 
ALPHLARD (Supplementary Notes). We further devised a methodology to statistically phase this 
germline variant set utilising 1000 Genomes Project40,50 haplotypes as a reference panel (Methods). 
The false discovery rate (FDR) of our site list was estimated to be <1% for SNVs, <1% for indels, <5% 
for deletions ≥50bp, <1% for MEIs, and 1% for multi-allelic short variants, respectively (Table 1, Table 
S2). Estimates for the non-reference genotype discordance were <1% and <3% for haplotype switch 
error rates at bi-allelic variants (excluding flip errors at rare reference panel sites), which we evaluated 
using haploid chromosomes from donor-matched tumour genomes (i.e., somatic whole chromosome 
losses; see Methods). 
 
We inferred donor population ancestry using a supervised version of the ADMIXTURE algorithm 
(Methods). The majority of PCAWG donors are of European (~75%) and East Asian (~15%) ancestry, 
reflecting the geographical distribution of ICGC and TCGA projects45 (Figure 1B, Extended Data Fig. 
1). Most germline variant sites (81.4%) represented rare alleles with minor allele frequency (MAF) 
<1%, and 23.5M (27.6%) of these were novel with respect to widely used DNA sequence variation 
archives (Figure 1C, Extended Data Fig. 2). And while only 35,459 (0.2%) of all common autosomal 
SNVs/indels (MAF≥1%) were novel with respect to sequence variation archives, our data notably 
comprise >250,000 common alleles not previously incorporated into public haplotype reference 
datasets, which in the future can be utilised in genome-wide association studies (GWAS) focussing on 
cancer and other phenotypes via imputation40 (Extended Data Fig. 2). 
 
We identified hundreds of likely deleterious frameshift, nonsense, and splice site disrupting variants 
leading to protein truncation (PTV) of 109 known autosomal cancer predisposition genes29 (Methods), 
affecting 11% of PCAWG donors (Figure 1D & Extended Data Fig. 3, Table S3). Germline PTVs 
among 183 DNA damage response genes48 without a presently established link to cancer risk were 
seen in another 20% of donors (Table S3). Testing for enrichment of rare variants with inferred 
functional consequence49 amongst annotated non-coding regulatory regions for this collective set of 
292 cancer predisposition and DNA damage response genes did not reveal evidence for enrichment 
(Supplementary Notes).  
 
As may be expected, previously reported cancer susceptibility SNPs identified though GWAS50-57 
exhibited enrichment for tumour types in which those SNPs were originally identified. This included 
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prostate cancer, chronic lymphocytic leukaemia (CLL), and melanoma, where polygenic risk scores 
(PRSs) showed elevation within the respective disease entity (P<0.001, Benjamini Hochberg-
corrected Wilcoxon test; Extended Data Fig. 3 & Supplementary Notes). Furthermore, patients with 
oesophageal adenocarcinoma showed PRSs indicative of susceptibility to melanoma suggesting 
potential commonalities in disease pathways. In CLL patients, high CLL-specific PRSs were correlated 
with young age at diagnosis (r=-0.23, P=0.02, Spearman rank correlation; Extended Data Fig. 3). 
 
Germline PTV association with mutation types implicates several genes in mutagenesis 
We next focused on investigating genetic determinants for somatic mutagenesis45. We performed rare 
variant burden tests (i.e. rare variant association analysis) to investigate the relationship of gene PTVs 
and somatic mutagenesis across cancers represented in PCAWG. To limit the number of hypotheses 
tested, we restricted our investigation to germline PTVs inferred amongst the 292 candidate genes 
(Table S3), with the reasoning that previous studies have successfully linked cancer predisposition 
genes and DNA damage response genes with patterns of somatic DNA alteration24,32.  Unless stated 
otherwise, analyses presented in the following were confined to donors of European ancestry and 
accounted for additional potential demographic, histological, and technical confounders (Methods). 
 
We first investigated single nucleotide substitutions, which we stratified by their local sequence context 
to account for the known sequence specificity of mutagenic processes16,18,44. This was achieved by 
considering in addition to each base substation, nucleotides at 5’ and 3’, which yielded trinucleotides 
corresponding to 96 mutation types16,44 (Fig. 2A). We identified nine genes displaying association 
between rare germline variants and the rate of substitution of at least one mutation type (Fig. 2AB), 
when adjusting FDR to 10% using the Benjamini-Hochberg procedure. These included genes with 
roles in (or interacting with proteins involved in) homologous recombination (HR) repair and DNA 
interstrand crosslink (ICL) repair (BRCA1, BRCA2, FANCD2, FANCM), base excision repair (NEIL1 
and MBD4), and other DNA damage-related cellular processes (MEN1, CHEK2, ALKBH3). Each of 
these genes showed enrichment or depletion of specific mutation types in conjunction with PTVs. For 
example, CHEK2 germline PTVs were associated with increased C>A and decreased T>G 
substitution rates, whereas BRCA2, NEIL1 and FANCM germline PTV carriers showed increased T>G 
substitution rates (Fig. 2BC).  
 
For some genes, the relative rates of somatic mutation type enrichment and depletion seen in 
germline PTV carriers, which can be summarized in the form of somatic mutation type spectra (briefly: 
mutation spectra; Fig. 2C), appeared to be broadly similar. For example, the mutational spectra of 
tumours arising in BRCA1, FANCD2, and FANCM germline PTV carriers were highly correlated 
(Spearman’s r≥0.6; Fig. 2D) to tumours arising in BRCA2 germline PTV carriers. To more closely 
investigate similarities and differences in mutation spectra we performed hierarchical clustering of 
genes in our list of 292 candidate loci for which at least four European germline PTV carriers existed in 
PCAWG. This analysis lends further support to the similarity in mutation spectra of these four genes 
and let us to infer additional genes, including PALB2 and FANCL that have known roles in HR and ICL 
repair pathways58,59, with correlated mutation spectra (Fig. 2DE)  
 
Defects in BRCA1 and BRCA2 have previously been implicated in an overrepresentation of mutations 
attributed to COSMIC mutation signature 3 (presumed to be mediated by a failure of DNA double-
strand break-repair by HR)44, prompting us to relate germline PTVs in these genes with NMF-based 
signature 3 estimates45. We detected signature 3 in 84% of BRCA1 and 73% of BRCA2 germline PTV 
variant carriers in PCAWG. Overall, 92% (46/50) of tumours with biallelic inactivation of 
BRCA1/BRCA2 (Table S4, Extended Data Fig. 4) were positive for signature 3 mutations and 
included ovarian (n=16), pancreatic (13), breast (12), prostate (2), and endometrial (1) cancers. 
Interestingly, none (0/8) of the monoallelic BRCA1/BRCA2 cases exhibited signature 3 mutations 
(P<2.5e-7; Fisher exact test), consistent with a requirement for inactivation of the wildtype allele in the 
context of BRCA1/BRCA2 deficiency58. An enrichment of signature 3 was also seen in PALB2, 
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FANCD2, and FANCM germline PTV carriers (OR=3.7, P=0.01) including in pancreatic, ovarian, 
breast, and liver cancers. Interestingly, none of these cases showed evidence for somatic inactivation 
of the wildtype allele. In summary, these results suggest that mutagenesis attributable to signature 3 
could be mediated by genetic defects in several members of the HR/ICL repair pathways. 
 
Closer inspection of mutation spectra in tumours emerging in donors harbouring germline PTVs in 
these HR and ICL repair genes showed that, whilst there was evidence for an increased relative 
frequency of most mutation types in germline PTVs carriers, C>T substitutions at CpG dinucleotides 
were relatively depleted (Fig. 2BCD). Notably, analysis of absolute mutation counts revealed that 
C>T substitutions at CpGs occurred at a similar frequency in carriers of BRCA1/2 germline PTVs as in 
donors lacking germline PTVs in BRCA1/2 (Extended Data Fig. 5) – which suggests that the 
respective DNA lesions may not be repaired by these genes. C>T mutations at CpGs result from the 
spontaneous hydrolytic deamination of 5-methylcytosine, a widespread process represented by 
mutation signature 1 active in normal tissues and cancers17,60. Mutation signature 1 has been found in 
all cancer types studied to date44, and results in a relevant set of cancer driver mutations61, prompting 
us to more carefully follow up this finding. 
 
Germline PTV association with mutational signature 1: MBD4 germline PTV carriers show 
increased rates of a widespread clock-like mutational process  
Intrigued by this observation, we performed a search for putative genetic determinants of the rate of 
mutation signature 1 – one of the most abundant mutational signatures across PCAWG tumor 
samples45 – based on germline PTVs within our set of 292 candidate genes. This analysis revealed 
MDB4 as the only candidate gene associated with mutational signature 1 (relative rate (RR)=4; P<1e-
5; Fig. 3A) implicating a gene that has not, to the best of our knowledge, previously been linked with 
the modulation of mutational processes in human cancer. We identified four carriers of diverse tumour 
types exhibiting heterozygous MBD4 PTVs amongst European donors (Table S3). Separate 
quantification of C>T mutations at CpG sites in these carriers based on NpCpG motif analysis 
(Supplemental Material) further substantiated the association with signature 1 mutagenesis resulting 
in further increased significance (RR=5; P<1e-7; Fig. 3B). MBD4 encodes a DNA glycosylase 
removing thymidines from T:G mismatches at methyl-CpG sites62, a functionality that may explain the 
germline-somatic association with mutation signature 1. The PTV-specific mutational type spectrum of 
MBD4 demonstrated, accordingly, highly specific enrichment for all four Np[C>T]pG mutation types 
(Fig. 3C). Notably, analysis of 8,337 previously published TCGA WES samples3,4, which included 14 
additional carriers of heterozygous germline MBD4 PTVs, replicated the association of MBD4 with 
somatic C>T transitions at CpGs (P=1e-3) based on nucleotide substitutions detectable in exome 
sequencing data (Fig. 3D).  
 
Mutational signature 1 was recently shown to represent a ubiquitous clock-like mutational process the 
abundance of which is highly correlated with donor age in a variety of histologies17 – and for which, to 
the best of our knowledge, a germline genetic determinant has not previously been reported. To 
further analyse the nature of this genetic factor, we subsequently performed analyses of MBD4 allelic 
state and gene expression, and investigated the genomic distribution of Np[C>T]pG substitutions in 
tumours emerging in MBD4 germline PTV carriers. Two out of the four (50%) European donors 
harbouring MBD4 germline PTVs displayed somatic loss of the MBD4 wildtype allele (Table S4), 
which may have augmented signature 1 mutagenesis in the respective tumour specimens. 
Investigation of different genomic features including gene density, heterochromatin and DNA 
replication timing suggested that somatic Np[C>T]pG mutagenesis is augmented throughout the 
genome in association with MBD4 germline PTVs (Extended Data Fig. 6). 
 
Gene expression profiling across cancers based on 1,220 PCAWG cancer samples with available 
transcriptome data63, notably, revealed an inverse correlation between MBD4 gene expression levels 
in tumors and mutational signature 1 levels (P=1.9e-21; Mann-Whitney U-test; Extended Data Fig. 6), 
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whereby tumours with low-level MBD4 expression showed more signature 1 mutations. This result 
lends further support to the relationship between MBD4 and signature 1, and suggests that MBD4 
expression differences may modulate levels of C>T mutations at CpGs across different tumour 
histologies.  
 
Germline PTV association with patterns of somatic indels and SVs 
We next analysed indels, which can form at considerable rates in cancer45,64. Employing rare variant 
burden testing across cancers amongst the set of 292 candidate genes revealed associations 
between somatic indels and germline PTVs in BRCA1, BRCA2, FANCD2, and MSH4 (Fig. 4A) – with 
MSH4 clustering with the former three genes, all of which are involved in HR repair, also in terms of 
mutation type spectra (Fig. 2E). Whereas all four genes showed association with elevated levels of 
indels ≥10bp in size, only BRCA2 associated with insertions and deletions 4-9bp in size, a finding 
further corroborated with ovarian and breast cancer samples exhibiting BRCA1 promoter 
hypermethylation known to mediate BRCA1 gene silencing65 (Fig. 4B, Extended Data Fig. 7). We 
additionally investigated germline PTVs in the context of microsatellite instability (MSI) 
(Supplementary Notes), identifying previously implicated genes of the DNA mismatch repair 
pathway33 as determinants for MSI (Extended Data Fig. 8). 
 
Somatic SVs, including balanced DNA rearrangements and copy-number alterations, represent the 
dominant form of mutation impacting cancer-related genes in several tumour types6,45. Employing rare 
variant association analysis across cancers, BRCA2 germline PTVs associated with somatic deletion 
(Fig. 4C) and BRCA1 germline PTVs with tandem duplication (Fig. 4D) rates, corroborating and 
further extending recent findings in breast cancer18,42. Deletion sizes were markedly reduced in 
BRCA2 germline PTV carriers compared to sporadic tumours, whereas duplication sizes showed a 
marked reduction in BRCA1 germline PTV carriers, an observation that we replicated in breast and 
ovarian cancers exhibiting BRCA1 promoter hypermethylation (Fig. 4E, Figure Extended Data Fig. 
7). Additionally, we detected a BRCA1 germline PTV in a single prostate cancer patient whose 
tumour, notably, displayed >400 small tandem duplications (<100 kb) (Fig. 4F) ranking first among all 
prostate cancers in PCAWG (n=210) with regard to somatic tandem duplication load. 
 
Analysis of somatic SV processes implicates BRCA1 deficiency in DNA replication errors 
Manual inspection of somatic SVs arising in BRCA1 germline PTV carriers showed that these 
occasionally manifest as more complex rearrangements linking distant genomic regions including 
regions on different chromosomes (Fig. 5A & Extended Data Fig. 9). These SVs typically exhibited 
inserted fragments at their breakpoints, and closer inspection showed that these fragments 
corresponded to duplicates of existing genomic regions, suggesting that they became copied from a 
pre-existing template rather than resulting from concurrent DNA breaks that became fragmented and 
subsequently repaired (Fig. 5A). Using rare variant burden testing across cancers we searched 
amongst our set of 292 candidate genes for PTVs associating with SVs that exhibit a breakpoint 
footprint of templated insertions, which we identified using a novel computational approach66 
(Methods). This analysis identified BRCA1 as the only gene associated with a templated insertions 
footprint, whereas BRCA2 germline PTVs showed association with a different footprint characteristic 
for balanced rearrangements (Fig. 5B). 
 
The presence of templated insertions at SV breakpoints suggests the activity of a DNA polymerase 
and hence replicative processes during somatic SV formation in conjunction with BRCA1 deficiency. 
Duplication of DNA sequence mediated by aberrant replication was previously studied primarily with 
respect to SV formation in congenital disorders67-69. In the context of aberrant DNA replication, 
template insertions have been attributed to low-processivity replication forks that switch templates and 
resume replication at a new site68. Complex rearrangements may arise in this context, given that 
relocated forks may themselves be prone to stalling and further template switching67,68.  
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To further corroborate our findings in conjunction with BRCA1 deficiency, we addressed the question 
whether a particular ‘SV formation process’ generating complex DNA alterations may operate in 
BRCA1-deficient cancers. To do so, we made use of a computational approach evaluating the 
proximity of adjacent rearrangement junctions as well as of the orientation and order of joined 
segments66 to classify somatic SVs into signatures. Comparing BRCA1 germline PTV carriers in 
ovarian cancer and breast cancer samples (representing 19 out of 27 BRCA1 PTV carriers in 
PCAWG) versus sporadically arisen ovarian and breast cancers, we identified a preponderance of 
BRCA1 PTV carriers to show two particular SV signatures. The first SV signature was characterized 
by relatively small tandem duplication events and cycles of templated insertions66 typically less than 
100kb in size, implicating aberrant re-replication of genomic loci, and formation of SVs through 
template switching, in the context of BRCA1 deficiency (Fig. 5C). The second SV signature was 
characterized by unbalanced translocations66, yet another form of somatic DNA rearrangement that 
appears to be increased in BRCA1 deficient tumours. Reassuringly, the relationship of germline PTVs 
in BRCA1 with these two signatures was further substantiated by a significant enrichment of the same 
two signatures in ovarian and breast cancers showing BRCA1 promoter hypermethylation (Fig. 5C). 
We additionally analysed BRCA2 germline PTV carriers using the same approach, identifying a 
preponderance of these to exhibiting three distinct somatic SV signatures66, including a signature 
characterized by deletions <10kb, a signature characterized by deletions of 10kb to 3Mb, and a 
signature characterized by reciprocal balanced rearrangements, respectively (P<0.05; Bonferroni 
correction).  
 
Intriguingly, samples with genetic or epigenetic BRCA1 inactivation also, occasionally, displayed much 
more complex rearrangement patterns – resulting in rearrangements that appear to involve series of 
highly inter-connected duplicative SVs. As one notable example, we detected 15 inter-linked relatively 
short duplicated segments in an ovarian cancer sample harbouring a germline BRCA1 PTV (median 
segment size 75kb; minimum=21kb; maximum=232kb; Fig. 5D). While the marked complexity 
precludes classification with our computational approach66, there are intriguing parallels with the 
signature of short tandem duplications and templated insertion cycles seen enriched in a BRCA1 
deficient context. Both event types oscillate around few copy-number states and both appear to 
involve interlinked duplicative segments, whereby some of the duplications partaking in the complex 
rearrangement shown in Fig. 5D – presenting distinct duplicative copy-number states – may have 
occurred on top of one another. Based on these observations it is an intriguing possibility that a 
duplication-mediated process leading to massively complex rearrangements different from 
chromothripsis (chromosome shattering involving segment deletions/losses22,24-27 rather than segment 
duplications) may have formed this event. We searched for interconnected clusters of duplications 
involving at least ten relatively short (<500kb) interlinked duplicated segments (i.e. complex 
rearrangements resembling the event shown in Fig. 5D; Supplementary Notes). Nineteen such 
putative events were detected across all PCAWG donors, three of which arose in a BRCA1-deficient 
context, suggesting an enrichment of these complex rearrangement structures in BRCA1-defective 
tumours (OR=12.7; P=0.0028, Fisher’s exact test; Fig. 5D, Extended Data Fig. 10, Extended Data 
File 1). The interconnected rearrangements and the copy-number oscillating nature of these suggest 
that these structures likely formed in a single SV formation event, perhaps as an extreme outcome of 
erroneous DNA replication. 
 
Common haplotypes at 11q22 and 22q13 implicated in somatic mutagenesis across cancers  
We next pursued a search for common germline polymorphisms (MAF>1%) associated with patterns 
of somatic mutation, by performing pan-cancer GWAS analyses for individual mutation types in 
European donors (Methods). These analyses identified a locus at 11q22 associated with overall 
mutation load at genome-wide significance (lead SNP rs12787749, MAF=1.1%, P=7.6e-11). This 
locus overlaps YAP1, an oncogene and effector of the Hippo tumor suppressor pathway70 (Extended 
Data Fig. 11). 
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We next considered mutational signatures, focusing on determinants of mutations attributed to the 
activity of the APOBEC family of cytidine deaminases, for which genetic determinants had previously 
been detected via locus-targeted analysis32,71. GWAS analysis showed no pan-cancer association for 
mutational signatures (2 and 13) attributed to APOBEC activity44 in Europeans (Extended Data Fig. 
11). Both signatures 2 and 13, however, represent composites of the enzymatic activity of APOBEC3A 
and APOBEC3B, which mediate mutagenesis in cancer at different activity levels72. We therefore 
refined this analysis by decomposing APOBEC mutation signatures into APOBEC3A-like (YTCA) and 
APOBEC3B-like (RTCA) signatures72, computing signature enrichments in a tetranucleotide context72 
(Supplementary Notes). Using the subset of PCAWG samples (N=1300) showing APOBEC3A-like 
and APOBEC3B-like signature enrichments (Supplement), we identified common genetic variants 
that associated with APOBEC3B-like signature enrichments at genome-wide significance (Fig. 6AB). 
The most strongly associated SNP was rs12628403 (P=3.35x10-11), which tags a deletion 
polymorphism fusing APOBEC3A with noncoding regions of APOBEC3B – a variant previously 
implicated in APOBEC mutagenesis and breast cancer risk32,71. Additionally, we identified a second 
locus, downstream of APOBEC3 (lead SNP rs9611067, ~300kb from rs12628403, P=2.89x10-9). We 
also observed strengthened associations amongst donors of East Asian ancestry (N=379), in whom 
the APOBEC3A/B deletion polymorphism is more frequent (P=2.82x10-14 for rs12628403,  
P=1.87x10-15 for rs9611067; Fig. 6C, Extended Data Fig. 11). 
 
Notably, cis-expression quantitative trait locus (eQTL) mapping pursued in lymphoblastoid cell lines73 
previously associated rs9611067 with APOBEC3B and APOBEC3A expression. Pan-cancer 
transcriptome analysis, which we performed across 1,047 PCAWG tumour samples with transcriptome 
data, showed that this eQTL extends to tumours with highest effect sizes measured for APOBEC3B 
(Fig. 6D, Extended Data Fig. 12). rs9611067 and rs12628403 are in strong linkage disequilibrium 
(LD) in Asians but not Europeans (r2=0.07 in Europeans and r2=0.41 in East Asians); analyses 
controlling for rs12628403 weakened but did not eliminate the association for rs9611067 (P=4.7e-05; 
see Supplement). Closer inspection of the relationship of these SNPs with APOBEC3B-like signature 
enrichment, notably, showed a more pronounced genetic effect for relatively low- to moderate-level 
than for high-level APOBEC3B-like signature enrichment, perhaps since samples with higher 
APOBEC3B-like mutagenesis are more prone to be influenced by environmental factors that mask 
genetic factors (Extended Data Fig. 12). Interestingly, we observed a reduction of viral (hepatitis B or 
C) infections amongst cancer samples from the Japanese liver cancer cohort, the largest tumor-type 
specific cohort in PCAWG74, in carriers of the rs9611067 risk allele (OR=0.29; P=0.02, Fisher’s exact 
test; Table S5). These findings suggest a possible interaction between APOBEC mutagenesis and 
infection (a potentially relevant environmental factor), or may result from APOBEC mutagenesis and 
viral infection both independently contributing to the disease. 
 
Over one hundred germline L1 source elements associated with somatic retrotransposition in 
cancer 
L1/LINE elements are a germline SV class with the ability to result in widespread somatic mutation 
through retrotransposition19,21,75,76, representing the third most abundant class of somatic SV in 
cancer45. L1 elements are a resource for cancer-driving mutations, which can involve somatic 
insertion-associated Megabase-sized DNA rearrangements and other mechanisms77-79. L1 
retrotransposition in cancer occurs through the activity of an as yet largely undetermined set of L1 
germline source loci, which we here aimed to characterize leveraging the unprecedented set of 2,642 
paired tumour and normal whole genomes. To trace somatic L1 events to individual germline source 
loci we searched for small tracks of L1-adjacent unique (non-repetitive) DNA sequences mobilised 
through L1 retrotransposition19,80-82, known as somatic L1-mediated transductions19,80-82, across all 
cancer samples in PCAWG. 
 
Doing so, we inferred the somatic activity of 124 germline L1 elements, including 75 that represent 
insertions with respect to the human reference genome, as well as 49 elements that are part of the 
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/208330doi: bioRxiv preprint first posted online Nov. 1, 2017; 
	 10	
reference assembly (Fig. 7A, Table S6). The majority (55%; 41/75) of polymorphic germline L1 source 
elements identified as insertions relative to the reference were novel with respect to current databases 
(Table S6). Irrespective of continental population ancestry, PCAWG donors typically exhibited 50–65 
germline source elements with the ability to promote retrotransposition in cancer (Extended Data Fig. 
13). We identified SNPs in strong LD (defined47 as r2≥0.8) for the majority of somatically active source 
elements inferred as polymorphic insertions (i.e., 53/68 germline L1s with MAF≥0.1%), which will 
facilitate identifying these active L1 source loci in future cancer genomics studies (Table S7). 
 
Overall, we inferred 2,923 L1-mediated transductions amongst 20,230 somatic retrotranspositions 
events identified among PCAWG donors77. 43% of cancer samples showed evidence for somatic 
retrotransposition, with notable enrichments for tumour types with high source element activity such as 
lung squamous carcinoma, oesophageal adenocarcinoma, and colorectal adenocarcinoma77. We 
observed notable differences in activity amongst L1 source elements. Sixteen moderate to high 
activity source loci contributed at least three transduction events on average in cancer genomes with 
detectable L1 activity, including rare L1 germline polymorphisms such as a novel element on 
chromosome 7p12.3 (variant allele frequency (VAF)≤1% in European and African populations) giving 
rise to 75 transductions amongst only six cancer samples with L1 activity (Fig. 7BC). By comparison, 
a previously described 22q12.1 source element19,83 detected across all donors of European, East 
Asian, African, South Asian and Native American ancestry exhibited more modest activity – yet owing 
to its fixed status contributed 22% of the transductions in PCAWG overall (Fig. 7B, Extended Data 
Fig. 13). Curiously, more active L1 source elements showed a preponderance towards rarer human 
population frequency (P=0.0015; Kruskal-Wallis rank sum test), with the rarest L1 source elements 
(VAF<1% across human populations) displaying ~3.5-fold higher activity than the most common 
source elements (VAF>5%) (Fig. 7D). According to classical theories for transposon evolution84, 
differences in the duration and intensity of selective pressures acting upon rare versus more common 
L1 elements may serve to explain this observation. Notably, some L1 germline source loci 
demonstrated signs of population-specificity, including a somatically active L1 source element on 
chromosome 10q25.1 with VAF=11% in donors of African ancestry, yet entirely absent in PCAWG 
donors of European and Asian ancestry as well as in 1000 Genomes Project40,50 donors of European 
and Asian ancestry (Fig. 7E and Supplementary Notes). 
  
Conclusions 
 
We report a novel resource comprising 88 million germline variants in 2,642 widely available cancer 
genomes, and demonstrate patterns of somatic mutation associated with germline PTVs, common 
SNPs and L1 source elements across diverse cancer types, which includes an association seen for a 
presumably population-specific somatically active L1 source element occurring in donors of African 
ancestry. 
 
Findings from our study reveal common genetic variants associated with somatic base substitution 
rates and processes at genome-wide significance, namely those associated with mutagenesis 
attributable to APOBEC3B. Additionally, we implicate BRCA1 germline PTV in complex SV patterns 
characterized by duplication-associated rearrangements likely mediated by aberrant DNA replication, 
an SV formation process that has remained under-studied in cancer. Replication-associated somatic 
SV formation may thus be more common than currently thought, and the BRCA1 gene may, in its 
intact form, serve to protect cells from such mutational events. Additionally, complex patterns of 
alterations we identified in conjunction with BRCA1-defects may facilitate accelerated karyotype 
evolution. By comparison, we implicated BRCA2 germline PTVs with somatic SV formation events 
likely to be initiated by DNA double strand breaks, including deletions and balanced DNA 
rearrangements.  
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Genes implicated in augmenting somatic mutation processes include some not previously reported as 
cancer predisposition genes. For example, our study implicates MSH4 with indel patterns and somatic 
base substitution spectra in cancer genomes similar to those seen in conjunction with HR repair 
deficiency (i.e. BRCA1 and BRCA2 PTVs), an observation that warrants follow-up studies given the 
relevance of HR repair deficiency for therapeutic targeting41. Evidence that MSH4 can augment the 
formation of short deletions, notably, has also been presented in yeast recently85. Elevation of 
mutation signature 1 in association with MBD4 germline PTV is, to our knowledge, the first 
demonstration of a heritable factor mediating inter-individual variation in the spontaneous hydrolytic 
deamination of cytosines at CpGs (which are commonly methylated) in humans. Signature 1 shows 
clock-like properties in tumour and normal tissues8,17,60,86 and may signify the number of post-zygotic 
divisions a cell has undergone17. Given its abundance across tissues8,17,60,86 and its correlation with 
patient age17, it has been suggested that signature 1 may influence ageing-related illnesses such as 
cancer8. If that is the case, this would render MBD4 a novel candidate risk gene for age-related 
pathologies including (and not limited to) cancer. Notably, MBD4 knockout (Mbd4−/−) in mice was 
found to promote gastrointestinal tumour formation, and mutation analyses pursued by targeting a 
~500bp-sized locus are consistent with increased spontaneous C>T transitions at CpGs in Mbd4−/− 
mice87, further supporting our findings based on human cancer genomes. Signature 1 partially 
recapitulates the pattern of de novo mutations in the germline17, raising the question whether MBD4 
germline PTV carriers may show increased germline mutations. Efforts to systematically catalogue de 
novo mutations in families88,89 could address this question in the future. 
 
Our study also has remaining limitations. Germline-somatic associations uncovered in our study 
mainly pertain to mutational patterns seen in a large fraction of donors, and depend on the number of 
germline variant carriers sampled in individual tumour types – a number that in spite of the inclusion of 
>2600 whole cancer genomes in our resource is inevitably going to be too small for candidate genes 
in which germline PTVs are relatively rare. In line with this, controlling the FDR at 20% (at “near 
significance”) let to a number of additional credible ‘hits’, including PALB2 and RECQL, which notably 
exhibited elevated indel and base substitution spectra similar to other HR genes (Extended Data Fig. 
14, Fig. 2DE). In the future, increased samples sizes are likely to provide insights into currently 
unexplained mutational signatures, including such restricted to particular tissues, on the basis of the 
approaches devised in our study. Mutation in cancer reflects the cumulative activity of different 
mutational processes, and our study identified a variety of associations between germline variants and 
somatic mutation, highlighting how variation in the germline can markedly shape cancer genomes.  
 
Finally, our dataset will likely show utility as a reference for prioritisation of rare pathogenic variants 
and imputation of common variants in cancer-focused disease studies, which is why we are releasing 
the full dataset (including genotype likelihoods) as a resource to the cancer community through 
standard data repositories (see “Data availability” below). The availability of both germline and somatic 
variants for each donor will facilitate utilisation of this reference resource for research on somatic 
mutation processes and putative germline cancer susceptibility variants. 
 
Data availability 
All data of our germline variant resource, including sequence alignment (BAM) files and haplotype-
block phased variant call files (VCF), are made available to the community via ICGC and TCGA-
associated PCAWG data portals45 (http://docs.icgc.org/pcawg) using controlled data access principles 
that have become standard in the cancer genomics community. Data releases can be accessed 
from the TCGA (dbGAP accession phs000178), the EGA (EGAS00001001692), and the ICGC 
(https://dcc.icgc.org/releases/PCAWG). 
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Figures and Tables 
 
Table 1. PCAWG germline variant callset based on ~39x (mean) coverage normal tissue whole 
genome sequencing read data from 2,642 cancer patients. FDR estimates are based on ultra-deep 
resequencing of randomly picked candidate variant sites in 48 PCAWG donors using custom 
sequence capture# for SNPs and indels; intensity rank sum (IRS)47 testing on the basis of Genome-
Wide Human SNP Array 6.0 datasets available for a subset (N=787) of PCAWG normal tissue 
samples* for SVs; and manual inspection of BAM files for a randomly selected subset of Alu, L1, SVA 
(for SINE-R–/VNTR–/Alu–based mobile elements), and endogenous retrovirus (ERV) insertions**. 798 
variant sites within HLA regions (exons of HLA-A, -B, -C, -DPA1, -DPB1, -DQA1, -DQB1, -DRB1), 
median size of 1bp (median kbp per individual: 0.320) were separately genotyped using custom 
methodology (Supplemental Notes). NA, not assessed. 
 
Germline variant  
class 
Number of 
sites 
Median 
site size 
Median kbp  
per individual 
Site  
FDR 
Biallelic SNPs  80,085,108 1bp 3,536 0.0043# 
     
Biallelic indels 5,888,176 2bp 789 0.0046# 
Multiallelic short variants 1,789,419 1bp 689 0.0117# 
Biallelic deletions ≥50bp 29,492 2743bp 2,805 0.0488* 
Alu insertions 19,641 312bp 371 0.0071** 
L1 insertions 3,623 1704bp 511 0.0102** 
SVA insertions 562 1275bp 61 0.0172** 
ERV insertions 29 NA NA 0.08** 
  Total        87,816,050  
.CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/208330doi: bioRxiv preprint first posted online Nov. 1, 2017; 
	 14	
Figure 1. Approach taken and properties of the PCAWG germline variant callset. (A) Approach 
taken by the PCAWG germline variation working group: integration of germline and somatic variation 
called in 2,642 cancer patients. (B) Continental population ancestry of donors per tumour type (for 
tumour type abbreviations, see45) stratified by study origin (Northern America for TCGA studies; 
different continents for ICGC studies). AFR, African ancestry; AMR, native American ancestry; EAS, 
East Asian ancestry; EUR, European ancestry; SAS, South Asian ancestry. Data shown for all tumour 
types represented by N≥10 donors. (C) Novelty per germline variant class. Shown is the number of 
novel, autosomal variants compared to the union of variants from dbSNP, the 1000 Genomes Project 
and the Haplotype Reference Consortium. Multi-allelic variants were decomposed into individual 
variants and indels were left-aligned. DEL, deletions≥50bp. (D) Germline loss-of-function (PTV) 
variants in cancer predispoisiton genes, by histology (blob diameters scale with the number of carriers 
per tumor type, from 1 to 14). 
 
Figure 2. Association of germline gene loss-of-function (PTV) variants with somatic mutation 
types. (A) Quantile-quantile (QQ) plot and volcano plot, exemplified for a single mutation type 
(C[C>A]C). (B) Summary of mutation types seen at 10% FDR (computed over all candidate genes 
represented by N≥4 germline PTV carriers), where 96 mutation types are sorted alphabetically. Closed 
circles: relative enrichment; open circles: relative depletion. Numbers in parentheses show the number 
of germline PTV carriers found by candidate gene. Blob diameters scale with log2 relative rates (RR) 
for individual mutation types, scales shown range from 0.5 to 1.2. Closed circles reflect positive, and 
open circles negative values. (C) PTV-specific mutation type spectra (briefly, mutation spectra) of 
BRCA1 and BRCA2. Relative rates (RR) shown are from our additive model, and control for potential 
confounders. (D) Pair-wise correlation shown for several selected mutation spectra of genes involved 
in HR and ICL repair. (E) Hierarchical clustering of mutation spectra, shown for all candidate genes 
with at least N=4 germline PTV carriers. 
 
Figure 3. Association of germline PTVs in MBD4 with elevated rates of somatic C>T mutation at 
CpG dinucleotides. (A) QQ and volcano plot showing association of MBD4 with mutation signature 1 
estimates across PCAWG histologies (European donors). (B) QQ and volcano plot showing 
association of MBD4 with C>T mutations at CpG dinucleotides inferred using a knowledge-based 
approach (by searching for C>T mutations with NpCpGs, in European donors). (C) Visualization of the 
somatic mutation spectrum observed in MBD4 germline PTV carriers. (D) Replication of MBD4 
association signal using TCGA exome sequencing data. A box plot depicts percentages of CpG>TpG 
mutations in tumours developing in MBD4 germline heterozygous PTV carriers versus non-carriers.  
 
Figure 4. Association of germline PTVs with somatic indels and SVs. (A) Summary of germline 
PTV / somatic indel associations computed over all candidate genes represented by N≥4 germline 
PTV carriers in European donors, across PCAWG. (B) Association of epigenetic BRCA1 gene 
silencing by promoter hypermethylation65 further substantiates specific somatic indel association with 
indel deletions >10bp (*denotes significance; 10% FDR). (C) QQ and volcano plot for SV deletions 
<10kb. (D) QQ and volcano plot for SV tandem duplications <10kb. (E) Somatic SV size spectrum 
shifts detected in association with germline PTVs in BRCA1 and BRCA2, respectively (see also 
Extended Data Fig. 7). Dashed/solid lines: tumours lacking/harbouring germline PTVs in BRCA1/2. 
(F) Prostate cancer sample with numerous tandem duplications, which arose in a BRCA1 germline 
PTV carrier. Abbreviations: Inter-chr., for inter-chromosomal; TD, for tandem duplication-type 
rearrangement; DEL, for deletion-type rearrangement; --/++, for inversion-type rearrangements (in the 
case of ++, reads point towards the q-telomere of a chromosome, and for -- towards the p-telomere, 
respectively). 
 
Figure 5. Association of germline PTVs with SV processes including complex patterns of SVs. 
(A) Example of a complex somatic SV in a breast cancer patient with BRCA1 germline deficiency, with 
duplicated areas/templated insertions from distinct genomic regions. (B) QQ plot showing association 
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of BRCA1 germline PTVs with SVs exhibting cycles of templated insertions, and BRCA2 germline 
PTVs with a balanced DNA rearrangement footprint. (C) Enrichment of an SV signature characterized 
by small tandem duplications and insertion cyles (“SV signature 9”)66 and an SV signature 
characterized by unbalanced translocations (“SV signature 5”) in BRCA1 germline PTV carriers. Both 
observations are further corroborated by similar enrichments in ovarian and breast cancers showing 
BRCA1 silencing via promoter hypermethylation (MWU for Mann-Whitney U test). (D) Highly complex 
rearrangement, potentially formed by DNA replication error-associated SV formation, in an ovarian 
cancer patient carrying a BRCA1 germline PTV. Differing copy-number states suggest that 
duplications may have occurred on top of one another during SV formation. 
 
Figure 6. Association of common germline variants with APOBEC cytidine aminase attributable 
mutagenesis. (A) Manhattan plot for APOBEC3B-like signature enrichment in European PCAWG 
donors. (B) Manhattan plot for APOBEC3A-like signature enrichment in European PCAWG donors. 
(C) Close up of significant peaks, Manhattan plot for APOBEC3B-like signature enrichment in East 
Asian PCAWG donors showing two independent association signals at the APOBEC3 gene cluster. 
(D) APOBEC3B relative gene expression in liver cancer samples from Japan versus allelic status of 
rs9611067. 
 
Figure 7. Germline L1 source elements driving somatic retrotransposition events in cancer. 
(A) Chromosomal map of germline L1 source elements with onferred somatic transduction activity. 
Elements with activity ‘0’ were identified as active in earlier studies, yet were not identified as active in 
PCAWG samples. (B) Source element contribution to L1-mediated transductions in PCAWG tumour 
samples versus variant allele frequency (VAF) in human populations (according to PCAWG germline 
genomic samples). The total number of transductions mediated by each source element and source 
element allele counts are shown as barplots. (C) A highly active germline L1 source element on 
chromosome 7 identified in donors of European and African ancestry (with VAF≤1%). (D) Higher 
inferred somatic L1 activities in rare compared to more common germline L1 source elements 
(P=0.0015; Kruskal-Wallis rank sum test). An outlying point observed for rare rare L1 source elements 
(VAF≤1%, inferred activity of 49) is shown at “≥20” (for visualization purposes). (E) L1 source 
elements seen in only one continental population. *Likely population-specific somatically active L1 
source element present at appreciable frequency in African donors (VAF~11%) as well as in African 
1000 Genomes Project samples (VAF~8%), yet entirely absent from European, East Asian and South 
Asian donors from PCAWG and the 1000 Genomes Project (see also Supplementary Note). 
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